Monoclonal antibodies reactive with endotoxin core
AssigneeCentocor, Inc.
InventorsMatthew Pollack, Kenneth W. Hunter
Life of this patent
Estimating the term…
Abstract
Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepa U.S. GOVERNMENT RIGHTS The invention described herein may be manufactured, used and licensed by or for the U.S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.
Claims17
A monoclonal antibody which binds to antigenic determinants in the endoxtoxin core of different genera of gram negative bacteria, said core consisting essentially of the lipid A and core oligosaccharide regions, and not the 0-side chain region of bacterial lipopolysaccharide, wherein said antibody:
- a) binds to endoxtoxin core from at least one species of gram negative bacteria from each of the genera of Escherichia, Salmonella and Pseudomonas;
- and,
- b) is effective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria when a therapeutically effective amount of said antibody is administered to the mammalian host.
A monoclonal antibody which binds to antigenic determinants in the endotoxin core of different genera of gram negative bacteria, said core consisting essentially of the lipid A and core oligosaccharide regions, and not the 0-side chain region of bacterial lipopolysaccharide, wherein said antibody:
- a) binds to endotoxin core from at least one species of gram negative bacteria from each of the genera of Escherichia, Salmonella and Pseudomonas;
- b) is effective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria when a therapeutically effective amount of said antibody is administered to the mammalian host;
- and,
- c) inhibits at least one biological response induced in mammalian cells by purified endotoxin in an in vitro assay.
A pharmaceutical composition comprising a monoclonal antibody and a pharmaceutically acceptable carrier, said antibody being one which binds to antigenic determinants in the endotoxin core of different genera of gram negative bacteria, said core consisting essentially of the lipid A and core oligosaccharide regions, and not the 0-side chain region of bacterial lipopolysaccharide, wherein said antibody:
- a) binds to endotoxin core from at least one species of gram negative bacteria from each of the genera of Escherichia, Salmonella and Pseudomonas;
- and,
- b) is effective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria when a therapeutically effective amount of said antibody is administered to the mammalian host.
A method of treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria by administering to said host a pharmaceutical composition comprising a therapeutically effective amount of monoclonal antibody in a pharmaceutically acceptable carrier, said monoclonal antibody binding to antigenic determinants in the endotoxin core of different genera of gram negative bacteria, wherein said core consists essentially of the lipid A and core oligosaccharide regions, and not the 0-side chain region of bacterial lipopolysaccharide, wherein said antibody;
- (a) binds to endotoxin core from at least one species of gram negative bacteria from each of the genera of Escherichia, Salmonella and Pseudomonas;
- and,
- (b) is effeective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria when a therapeutically effective amount of said antibody is administered to the mammalian host.
A method of inhibiting clinical manifestations of infection in a mammalian host caused by gram negative bacteria by administering to said host a pharmaceutical composition comprising a prophylactically effective amount of monoclonal antibody in a pharmaceutically acceptable carrier, said monoclonal antibody binding to antigenic determinants in the endotoxin core of different genera of gram negative bacteria, wherein said core consists essentially of the lipid A and core oligosaccharide regions, and not the 0-side chain region of bacterial lipopolysaccharide, wherein said antibody:
- (a) binds to endotoxin core from at least one species of gram negative bacteria from each of the genera of Escherichia, Salmonella and Pseudomonas;
- and,
- (b) is effective in treating clinical manifestations of infection in a mammalian host caused by gram negative bacteria when a therapeutically effective amount of said antibody is administered to the mammalian host.
Dependencies are inferred from the claim text.